BRIEF-Veru Receives FDA Agreement To Advance Veru-111 Into Phase 3 Study In Hospitalized Covid-19 Patients At High Risk For Acu
BRIEF-Veru Receives FDA Agreement To Advance Veru-111 Into Phase 3 Study In Hospitalized Covid-19 Patients At High Risk For Acu
* VERU RECEIVES FDA AGREEMENT TO ADVANCE VERU-111 INTO PHASE 3 STUDY IN HOSPITALIZED COVID-19 PATIENTS AT HIGH RISK FOR ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS)
* VERU INC - VERU COMPLETES EXPEDITED END OF PHASE 2 TRIAL MEETING WITH FDA
* VERU INC - PHASE 3 CLINICAL STUDY EXPECTED TO BEGIN IN APRIL 2021 WITH CLINICAL RESULTS EXPECTED IN CALENDAR Q4 2021
* VERU INC - FDA AGREES TO ADVANCE VERU-111 INTO PHASE 3 CLINICAL STUDY IN HOSPITALIZED HIGH RISK COVID-19 PATIENTS TO CONFIRM POTENTIAL BENEFIT & RISK
* VERU -FDA AGREES CLINICAL FINDINGS SUGGEST CLINICALLY MEANINGFUL BENEFIT FOR USE OF VERU-111 IN HOSPITALIZED COVID-19 PATIENTS AT HIGH RISK FOR ARDS
Source text for Eikon: Further company coverage:
((Reuters.Briefs@thomsonreuters.com;)
March 1 (Reuters) - Veru Inc :
* VERU RECEIVES FDA AGREEMENT TO ADVANCE VERU-111 INTO PHASE 3 STUDY IN HOSPITALIZED COVID-19 PATIENTS AT HIGH RISK FOR ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS)
* VERU INC - VERU COMPLETES EXPEDITED END OF PHASE 2 TRIAL MEETING WITH FDA
* VERU INC - PHASE 3 CLINICAL STUDY EXPECTED TO BEGIN IN APRIL 2021 WITH CLINICAL RESULTS EXPECTED IN CALENDAR Q4 2021
* VERU INC - FDA AGREES TO ADVANCE VERU-111 INTO PHASE 3 CLINICAL STUDY IN HOSPITALIZED HIGH RISK COVID-19 PATIENTS TO CONFIRM POTENTIAL BENEFIT & RISK
* VERU -FDA AGREES CLINICAL FINDINGS SUGGEST CLINICALLY MEANINGFUL BENEFIT FOR USE OF VERU-111 IN HOSPITALIZED COVID-19 PATIENTS AT HIGH RISK FOR ARDS
Source text for Eikon: Further company coverage:
((Reuters.Briefs@thomsonreuters.com;)
路透3月1日電-Veru Inc:*VERU獲得食品和藥物管理局的同意,將VERU-111推進到住院的新冠肺炎急性呼吸窘迫綜合徵高危患者的3期研究*Veru Inc-Veru完成與FDA的第二階段試驗會議的加速結束*Veru Inc-3期臨牀研究預計將於2021年4月開始,臨牀結果預計將於2021年第四季度公佈*VERU INC-FDA同意將VERU-111推進到住院的高危新冠肺炎患者的3期臨牀研究,以確認潛在的益處和風險*VERU-FDA同意臨牀研究結果表明,在住院的新冠肺炎患者中使用VERU-111對急性呼吸窘迫綜合徵的高危患者有臨牀意義的益處Eikon的源文本:進一步的公司報道:(Reurs.Briefs@thomsonreurs.com;)
譯文內容由第三人軟體翻譯。
風險及免責聲明
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧